HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yuan Liu Selected Research

GSK 1363089

1/2021Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
5/2017A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.
1/2013Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
3/2011Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yuan Liu Research Topics

Disease

345Neoplasms (Cancer)
12/2022 - 02/2005
88Infections
10/2022 - 02/2008
69Inflammation (Inflammations)
01/2022 - 02/2004
68Breast Neoplasms (Breast Cancer)
04/2022 - 12/2006
43Neoplasm Metastasis (Metastasis)
01/2022 - 02/2005
39Fibrosis (Cirrhosis)
03/2022 - 04/2011
27Hepatocellular Carcinoma (Hepatoma)
01/2022 - 01/2005
26Prostatic Neoplasms (Prostate Cancer)
03/2022 - 04/2009
24Body Weight (Weight, Body)
01/2022 - 03/2011
24Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 05/2009
21Lung Neoplasms (Lung Cancer)
01/2022 - 11/2009
20Pain (Aches)
10/2022 - 12/2010
20Hypoxia (Hypoxemia)
01/2022 - 09/2011
20Carcinoma (Carcinomatosis)
12/2021 - 10/2004
20Carcinogenesis
11/2021 - 10/2010
19Obesity
01/2022 - 11/2011
18Stomach Neoplasms (Stomach Cancer)
06/2022 - 01/2013
18Type 2 Diabetes Mellitus (MODY)
01/2021 - 06/2011
17Wounds and Injuries (Trauma)
10/2022 - 12/2005
17Uterine Cervical Neoplasms (Cancer of the Cervix)
05/2022 - 04/2013
17Hypertension (High Blood Pressure)
01/2022 - 01/2013
17Insulin Resistance
05/2021 - 06/2011
16Renal Cell Carcinoma (Grawitz Tumor)
01/2022 - 01/2010
16Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 07/2013
16Adenocarcinoma
01/2022 - 10/2004
14Aortic Dissection
11/2022 - 02/2008
14Heart Failure
01/2022 - 11/2003
13COVID-19
06/2022 - 01/2020
12Squamous Cell Carcinoma (Epidermoid Carcinoma)
08/2022 - 06/2008
12Reperfusion Injury
02/2022 - 05/2011
12Stroke (Strokes)
01/2022 - 09/2011
12Myocardial Infarction
01/2022 - 07/2010
12Hemorrhage
12/2021 - 04/2008
12Cardiovascular Diseases (Cardiovascular Disease)
10/2021 - 03/2009
12Cardiomegaly (Heart Hypertrophy)
11/2019 - 09/2012
11Bacterial Infections (Bacterial Infection)
10/2022 - 03/2015
11Diabetes Mellitus
04/2022 - 12/2013
11Ischemia
02/2022 - 01/2009
11Non-alcoholic Fatty Liver Disease
01/2022 - 11/2011
11Thymoma (Thymic Carcinoma)
02/2021 - 04/2016
10Osteoarthritis
01/2022 - 01/2015
10Hypertrophy
10/2021 - 05/2014
10Pulmonary Fibrosis (Fibrosing Alveolitis)
01/2021 - 07/2014
10Colonic Neoplasms (Colon Cancer)
01/2020 - 08/2005
9Thrombocytopenia (Thrombopenia)
01/2022 - 01/2010
9Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 09/2015
9Colitis
01/2022 - 12/2011

Drug/Important Bio-Agent (IBA)

111Proteins (Proteins, Gene)FDA Link
11/2022 - 10/2004
65Biomarkers (Surrogate Marker)IBA
11/2022 - 10/2010
57Pharmaceutical PreparationsIBA
03/2022 - 01/2006
38CytokinesIBA
10/2022 - 12/2006
35Biological ProductsIBA
01/2022 - 09/2007
32Messenger RNA (mRNA)IBA
11/2022 - 10/2004
32Glucose (Dextrose)FDA LinkGeneric
03/2022 - 06/2011
28MicroRNAs (MicroRNA)IBA
03/2022 - 12/2011
24Hormones (Hormone)IBA
01/2022 - 07/2008
22Anti-Bacterial Agents (Antibiotics)IBA
10/2022 - 04/2015
22DNA (Deoxyribonucleic Acid)IBA
04/2022 - 02/2008
19Therapeutic UsesIBA
01/2022 - 02/2008
18EnzymesIBA
01/2022 - 05/2007
18LigandsIBA
01/2022 - 12/2004
17LipidsIBA
04/2022 - 04/2011
15Indicators and Reagents (Reagents)IBA
11/2022 - 02/2004
15Immune Checkpoint InhibitorsIBA
01/2022 - 12/2019
14Long Noncoding RNAIBA
02/2022 - 01/2017
13RNA (Ribonucleic Acid)IBA
03/2022 - 04/2014
13palbociclibIBA
01/2022 - 01/2018
13Small Interfering RNA (siRNA)IBA
12/2021 - 03/2008
13VaccinesIBA
01/2021 - 05/2010
12LipopolysaccharidesIBA
01/2022 - 05/2010
12Doxorubicin (Adriamycin)FDA LinkGeneric
01/2022 - 01/2006
12ErbB Receptors (EGF Receptor)IBA
01/2022 - 06/2013
12Peptides (Polypeptides)IBA
12/2021 - 02/2004
12Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2021 - 03/2008
11Reactive Oxygen Species (Oxygen Radicals)IBA
08/2022 - 03/2014
11AutoantibodiesIBA
03/2022 - 01/2015
11Oxygen (Dioxygen)IBA
03/2022 - 12/2011
11Interleukin-6 (Interleukin 6)IBA
01/2022 - 05/2010
11Insulin (Novolin)FDA Link
08/2021 - 06/2011
11Estrogen ReceptorsIBA
01/2021 - 09/2009
10Tigecycline (Tygacil)FDA Link
02/2022 - 01/2020
10UbiquitinIBA
01/2022 - 11/2013
10AntigensIBA
01/2022 - 05/2010
10Phosphotransferases (Kinase)IBA
01/2022 - 08/2005
10Streptozocin (Streptozotocin)FDA Link
12/2021 - 10/2016
10Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 01/2012
10AntioxidantsIBA
01/2021 - 05/2013
9AndrogensIBA
03/2022 - 01/2020
9CholesterolIBA
01/2022 - 02/2012

Therapy/Procedure

192Therapeutics
08/2022 - 06/2005
61Drug Therapy (Chemotherapy)
10/2022 - 05/2007
49Radiotherapy
04/2022 - 01/2007
24Immunotherapy
10/2022 - 01/2018
21Liver Transplantation
01/2021 - 10/2008
16Endovascular Aneurysm Repair
01/2022 - 06/2011
14Transplantation
04/2022 - 12/2005
11Stents
11/2022 - 02/2008
11Chinese Traditional Medicine (Traditional Chinese Medicine)
05/2022 - 09/2007
9Length of Stay
08/2022 - 04/2015
9Aftercare (After-Treatment)
04/2022 - 07/2013